For Elroy, a special moment is reading his granddaughter her favorite story, or getting out on the court to teach his grandsons how to shoot a jump shot. A few years ago, Elroy had a heart attack, then another one. His heart was failing.
Until she fainted in 2012, Alicia didn’t know she was sick. Feeling tired and out of breath were “normal for me,” says the now 52-year-old single mom. The Glenside resident believed she felt that way because she was overweight and out of shape. She was working 10- to 12-hours daily attending her daughter Shannon’s high school track meets and working part-time on an online MBA degree.
Over the last two decades, MCSDs have been developed to augment or supplant failing myocardial performance. This therapy has been used successfully as a bridge to heart transplantation, a bridge to recovery, and as permanent implantation or "destination therapy" for intractable heart failure. Although heart transplantation offers life-saving therapy for selected patients, its use is limited by a supply of donor organs that currently meets less than one-tenth the need. As a consequence, the number of MCSD implantations has increased in recent years.
The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction (HFrEF) when...